BR112018072511A2 - métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica - Google Patents

métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica

Info

Publication number
BR112018072511A2
BR112018072511A2 BR112018072511A BR112018072511A BR112018072511A2 BR 112018072511 A2 BR112018072511 A2 BR 112018072511A2 BR 112018072511 A BR112018072511 A BR 112018072511A BR 112018072511 A BR112018072511 A BR 112018072511A BR 112018072511 A2 BR112018072511 A2 BR 112018072511A2
Authority
BR
Brazil
Prior art keywords
strain
allergy
prophylaxis
inhibition
treatment
Prior art date
Application number
BR112018072511A
Other languages
English (en)
Inventor
Priya GANESH Bhanu
Möllstam Bo
Versalovic James
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of BR112018072511A2 publication Critical patent/BR112018072511A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

as cepas bacterianas úteis na profilaxia, inibição e/ou tratamento de uma alergia em um mamífero são selecionadas por rastreamento de cepas bacterianas quanto à capacidade de produzir diacilglicerol quinase (dagk). uma cepa bacteriana que é capaz de produzir dagk é então selecionada para uso na profilaxia, inibição e/ou tratamento da alergia.
BR112018072511A 2016-05-09 2017-05-08 métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica BR112018072511A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650620 2016-05-09
PCT/SE2017/050455 WO2017196235A1 (en) 2016-05-09 2017-05-08 Selection of bacterial strains useful in allergy treatment

Publications (1)

Publication Number Publication Date
BR112018072511A2 true BR112018072511A2 (pt) 2019-03-12

Family

ID=58873850

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072511A BR112018072511A2 (pt) 2016-05-09 2017-05-08 métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica

Country Status (11)

Country Link
US (2) US11135255B2 (pt)
EP (1) EP3454874A1 (pt)
JP (1) JP7030716B2 (pt)
CN (1) CN109195612A (pt)
AU (1) AU2017262408A1 (pt)
BR (1) BR112018072511A2 (pt)
CA (1) CA3023867A1 (pt)
CL (1) CL2018003167A1 (pt)
MX (1) MX2018013660A (pt)
SG (1) SG11201809551TA (pt)
WO (1) WO2017196235A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021136951A (ja) * 2020-03-06 2021-09-16 学校法人麻布獣医学園 乳酸菌含有組成物
CN113073066B (zh) * 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
CN114317326B (zh) * 2021-12-06 2023-09-12 浙江工商大学 一种用于缓解过敏反应的清酒乳杆菌及制备方法
CN115025130A (zh) * 2022-06-02 2022-09-09 广东南芯医疗科技有限公司 罗伊氏乳杆菌e9在制备治疗或预防过敏性疾病药物中的应用
CN116376758A (zh) * 2023-03-15 2023-07-04 广东南芯医疗科技有限公司 詹氏乳杆菌ls06及其在制备治疗或预防过敏性疾病药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK154078C (da) * 1981-02-06 1989-05-22 Ucb Sa Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
KR100507417B1 (ko) 2003-01-27 2005-08-10 (주) 피엘바이오 알레르기 질환 예방 및 치료 기능을 가진 유산균과 이를 함유한 항알레르기 제품
US20080269239A1 (en) * 2004-11-11 2008-10-30 Argenta Discovery Ltd. Pyrimidine Compounds as Histamine Modulators
US8017592B2 (en) * 2006-04-13 2011-09-13 Alcon Research, Ltd. RNAi-mediated inhibition of histamine receptor H1-related conditions
JP2008127365A (ja) * 2006-11-24 2008-06-05 Kowa Co アレルギー性疾患の予防及び／又は治療剤
WO2010020057A1 (en) * 2008-08-18 2010-02-25 Manel Jordana Treatment and/or Prevention of Peanut Induced Anaphylaxis
JP2011254773A (ja) 2010-06-11 2011-12-22 Bio Plan:Kk 乳酸菌の菌株及びこれを利用したアレルギー抑制剤
WO2012012390A1 (en) * 2010-07-19 2012-01-26 Marvphyt Development Llc Botanical composition and methods of manufacture and use
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
JP6195268B2 (ja) * 2013-07-18 2017-09-13 国立大学法人徳島大学 鼻炎の予防治療装置
CN107709541A (zh) * 2015-03-26 2018-02-16 拜奥加亚公司 产生组胺的细菌菌株和它们在癌症中的用途

Also Published As

Publication number Publication date
CA3023867A1 (en) 2017-11-16
WO2017196235A1 (en) 2017-11-16
CN109195612A (zh) 2019-01-11
JP7030716B2 (ja) 2022-03-07
SG11201809551TA (en) 2018-11-29
US11135255B2 (en) 2021-10-05
AU2017262408A1 (en) 2018-11-15
JP2019520801A (ja) 2019-07-25
MX2018013660A (es) 2019-02-28
EP3454874A1 (en) 2019-03-20
CL2018003167A1 (es) 2018-12-21
US20220008491A1 (en) 2022-01-13
US20190142877A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
BR112018072511A2 (pt) métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
GT201400111A (es) Triazolopiridinas sustituidas
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
BR112017009545A2 (pt) composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo
BR112017008595A2 (pt) composições e métodos referentes à beta-glucosidase
BR112016023754A2 (pt) ?uso de lactobacillus paracasei para promover recuperação da diversidade da microbiota intestinal após disbiose?
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
BR112017019750A2 (pt) processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
BR112016030294A2 (pt) Cepa de bactérias probióticas de lactobacillus e uma vacina de aves domésticas, composição, ovo de aves domésticas embrionado, kit, e, método de vacinação in ovo de aves domésticas
AR088670A1 (es) Metodo de control del peso

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]